Rick Lifsitz, MBA

Corrigendum

Corrigendum: Could the Lack of an Efficient and Affordable Diagnostic Pathway Limit Market Access for New Alzheimer`s Treatments?

08/02/2016

Rick Lifsitz, MBA

Larry Blandford, PharmD—Column Editor

In the June 2016 article, “Could the Lack of an Efficient and Affordable Diagnostic Pathway Limit Market Access for New Alzheimer’s Treatments?"1 the author and column editor would like to clarify several points....

In the...

08/02/2016

Journal of Clinical Pathways

Pharma Insights

Could the Lack of an Efficient and Affordable Diagnostic Pathway Limit Market Access for New Alzheimer`s Treatments?

06/20/2016

Rick Lifsitz, MBA

Larry Blandford, PharmD—Column Editor

The promise in the coming years of a novel therapeutic to slow the progression of the debilitating effects of Alzheimer’s disease (AD) is exciting and represents a monumental step forward in treating patients with...

The...

06/20/2016

Journal of Clinical Pathways